Pharmaceutical Technology
MAY 31, 2023
C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China region. It is expected to accelerate the development of CFT8919 in important international markets.
XTalks
MARCH 1, 2021
Pfizer/BioNTech are executing the three-dose study to also determine the effectiveness of a third dose against evolving variants as part of their clinical development strategy. Sera from individuals will also be taken to evaluate neutralization of different SARS-CoV-2 strains in in vitro studies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 14, 2020
Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. AbbVie has initiated a Phase I clinical trial of the antibody, and it will conduct the initial clinical program in the U.S.
Pharmaceutical Technology
MAY 26, 2023
Doggybone DNA is named for its bone-shaped schematic structure and produced using an in vitro enzymatic process over 50 days, which is more than five times quicker than the 270 days taken for plasmid DNA E.Coli fermentation process. One big pharma company has already given the seal of approval with a successful customer quality audit.
The Pharma Data
JANUARY 12, 2021
Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Dr. Graham earned an M.D.,
The Pharma Data
APRIL 4, 2022
Chief Medical Officer and Head of Global Product Development, Roche. today announced that the U.S. A decision on U.S. FDA approval is expected in the second half of this year. 7 Implementing an international differentiated pricing strategy specifically designed to address needs during this pandemic and improve affordability.7
The Pharma Data
MARCH 29, 2022
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 2 subvariant, now the dominant strain in Europe. 1-3 Evusheld was generally well-tolerated in the trial. Christoph D.
Expert insights. Personalized for you.
130 
Let's personalize your content